IRCT20200105046010N49招募中未知
In- Vivo Bioequivalence study of Empagliflozin tablet (EMPATUS® 25 mg Pars Darou Pharma., Iran) with brand drug (JARDIANCE® 25 mg, Boehringer Ingelheim, Germany) in Iranian healthy
Pars Darou Pharm. Co.0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •General health
- •Body mass index between18-28
- •Informed consent
- •Being at the age of 18-55 years old
排除标准
- •A history of cardiovascular disease
- •A history of liver & kidney disease
- •Alcohol & Drug addiction
- •Hypersensitivity to the drug
研究者
相似试验
尚未招募
不适用
Empagliflozin, Linagliptin tablet 25, 5mg ABIDI (Glorenta 25, 5mg), In- Vivo Bioequivalence in Iranian healthy volunteers.IRCT20200105046010N4Tabriz University of Medical Sciences24
招募中
不适用
In-vivo Bioequivalence Test of Empagliflozin-Metformin tablets with brand drug (Synjardy® 25/1000 mg, Boehringer Ingelheim, Germany)Bio equivalence test.IRCT20200105046010N60Pars Darou Pharmaceutical Company24
尚未招募
不适用
Bioequivalence study of Empagliflozin 12.5 mg+ Metformin 1000 mg in 24 healthy male under fasting conditionsIRCT20180620040164N13ACtover Pharmaceutical Co26
招募中
不适用
Bioequivalence study of Empagliflozin 25 mg tablet in 24 healthy male under fasting conditionsBioequivalence investigation of the generic Actoverco. Empagliflozin 25 mg tablet with brand Jardiance 25 mg tablet Boehringer..IRCT20180620040164N19Actover Pharmaceutical Co.24
尚未招募
Unknown
Bioequivalence Study of Empagliflozin/Linagliptin 25/5 mg Kharazmi Pharma CoThis study is performed on healthy volunteers and drug concentration in plasma is determined..IRCT20200105046010N97Kharazmi Pharmaceutical Co24